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Abstract
Background: To promote early diagnosis and treatment of short stature, consensus meetings
were held in the mid nineteen nineties in the Netherlands and the UK. This resulted in guidelines
for referral. In this study we evaluate the referral pattern of short stature in primary health care
using these guidelines, comparing it with cut-off values mentioned by the WHO.
Methods: Three sets of referral rules were tested on the growth data of a random sample (n =
400) of all children born between 01-01-1985 and 31-12-1988, attending school doctors between
1998 and 2000 in Leiden and Alphen aan den Rijn (the Netherlands): the screening criteria
mentioned in the Dutch Consensus Guideline (DCG), those of the UK Consensus Guideline
(UKCG) and the cut-off values mentioned in the WHO Global Database on Child growth and
Malnutrition.
Results: Application of the DCG would lead to the referral of too many children (almost 80%).
The largest part of the referrals is due to the deflection of height, followed by distance to target
height and takes primarily place during the first 3 years. The deflection away from the parental
height would also lead to too many referrals. In contrast, the UKCG only leads to 0.3% referrals
and the WHO-criteria to approximately 10%.
Conclusion: The current Dutch consensus guideline leads to too many referrals, mainly due to
the deflection of length during the first 3 years of life. The UKCG leads to far less referrals, but may
be relatively insensitive to detect clinically relevant growth disorders like Turner syndrome. New
guidelines for growth monitoring are needed, which combine a low percentage of false positive
results with a good sensitivity.
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Background
Monitoring children's growth and development is fully
integrated in preventive health care programmes through-
out the world. In developing countries growth monitor-
ing, implying regular height and weight measurements, is
primarily aimed at identifying malnutrition to reduce
mortality, whereas in industrialised countries it is mainly
used to detect disorders associated with growth failure.
The effect of routine growth monitoring in developing
countries has recently been questioned [1]. Its efficacy and
efficiency in developed countries has hardly been studied,
and a recent international inquiry showed that there is
considerable variability in growth monitoring practices
worldwide [2].
The primary aim of growth monitoring in industrialised
countries is to detect growth disorders at an early age, thus
the sensitivity (a statistical measure of how well the test
correctly identifies a condition) of the screening proce-
dure should be high at a young age. Poor growth can be
caused by a great diversity of congenital or acquired con-
ditions, some of which present with additional symptoms
and signs. In other conditions, such as Turner syndrome,
Growth Hormone Deficiency (GHD) and celiac disease,
additional clinical features may be absent. Still, in such
disorders early diagnosis and treatment is important,
because early treatment has an optimal effect on growth in
childhood, as well as on final height, expectedly resulting
in a better quality of life. The second aim of growth mon-
itoring is to keep the number of healthy children referred
for further investigation at a minimum, meaning that the
specificity should be very high.
In order to diminish the uncertainty among health work-
ers in preventive child health care about the auxological
criteria (auxology is the scientific study of growth) on
which the decision to refer a child for further diagnosis
should be based, and the resulting wide variation in the
way growth monitoring is carried out, in 1996 a consen-
sus meeting was held in the Netherlands on "Diagnosis of
short stature in childhood". At this meeting representa-
tives of general practitioners, well-baby clinic doctors,
school doctors, paediatricians and paediatric endocrinol-
ogists came to a consensus guideline on referral criteria for
aberrant growth [3]. Although the authors had aimed at
promoting early diagnosis of aberrant growth as well as at
preventing unnecessary referral and interventions, it was
shown later that if this guideline would be followed, an
unacceptable percentage of healthy children would be
referred [4]. In the United Kingdom a similar consensus
meeting on diagnosis of short stature was held, resulting
in a guideline restricted to aberrant height at the age of 5
years, with assumingly a better specificity, but an
unknown sensitivity to detect disorders timely [5,6].
In the present study we wished to 1) study the perform-
ance of the Dutch Consensus Guideline (DCG) in a sec-
ond sample with a wider age range; 2) count the actual
referrals for short stature in that region; and 3) investigate
the test characteristics of the UK Consensus Guideline
(UKCG), WHO guideline and several other referral rules.
This study was part of a larger program aimed at produc-
ing an evidence-based guideline on growth monitoring, in
which we earlier investigated the best auxological criteria
to detect Turner syndrome [7] Celiac Disease (van Dom-
melen et al, submitted), and Cystic Fibrosis (Grote et al,
submitted).
Methods
We performed a retrospective observational study in pri-
mary health care. A random sample (n = 400) of all chil-
dren born between 01-01-1985 and 31-12-1988,
attending school doctors between 1998 and 2000 in Lei-
den and Alphen aan den Rijn (located in the northern part
of the province Zuid-Holland, at the western side of the
Netherlands) was drawn from files of the regional public
health organization (every 15th  file). The DCG was
believed to be well known to the health personnel during
the study period. There were no exclusion criteria.
The following baseline data and other observations, col-
lected by the well-baby clinics and the school health serv-
ices, were obtained from the medical records: date of
birth; sex; height of parents; date and outcome of the dif-
ferent measurements of height and weight of the child
since birth; presence of dysmorphic features or dispropor-
tion; birth weight and length, gestational age; and infor-
mation about referral(s) to a specialist (date and reason).
If ethnicity was not recorded, it was estimated based on
the patient's first and family name according to an algo-
rithm reported earlier [8]. If health records were incom-
plete, a short questionnaire was sent to all children in
2004 to obtain additional data on medical history, paren-
tal height and current height.
Three sets of referral rules were tested on the growth data:
the auxological criteria mentioned in the DCG [3], those
of the UKCG [5] and the cut-off values mentioned in the
WHO Global Database on Child growth and Malnutrition
[9]. While the UKCG concentrates only on one auxologi-
cal referral criterion (Height < -2.67 SDS (= 0.4th centile)
at the age of 5 years [5]), the DCG [3] focuses on several
referral criteria : Height in standard deviation score (SDS),
Clinical symptoms (indications of psychosocial growth
retardation, dysmorfic or disproptionate features), persist-
ent short stature after born SGA (small for gestational
age), HSDScor (the distance between height SDS and the
target height SDS (the estimated final height SDS of a boy
or a girl on the basis of their genetic potential), and
growth deflection (a downward movement of height SDS)BMC Public Health 2007, 7:77 http://www.biomedcentral.com/1471-2458/7/77
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(table 1). Target height (TH) for a boy is [father's height +
(mother's height + 13)]/2 + 4.5 cm and for a girl:
[mother's height + (father's height - 13)]/2 +4.5 cm,
wherein 13 cm is the mean difference between final
height of males and females, and 4.5 cm is the mean sec-
ular trend in one generation of 30 years. Target height can
also be expressed as SDS (Z-score), by taking the differ-
ence between TH and the mean final height of a young
adult of the same sex, and then divide by the SD at that
age. By correcting for secular trend, the actual population
reference diagrams can be used for calculating TH SDS.
The WHO Global Database on Child growth and Malnu-
trition uses a cut-off point of -2 SD (= 2.3rd centile) to clas-
sify stunting (low height for age) and underweight at all
ages [9].
Because of the instability in growth pattern under the age
of three years and the varying growth patterns in puberty
caused by differences in pubertal timing, we decided to
evaluate the guidelines in different age groups (0–3, 3–10
and 10–18 years), as well as over the whole age range. As
it was hypothesized that in the age group 0–3 years a
height deflection in standard deviations scores (SDS)
away from the target height SDS might be a good reason
to refer, we decided to test this rule (| HSDS (x2)- TH SDS
| > | HSDS(x1) – TH SDS |) for both a delta HSDS (HSDS
(x2)-HSDS(x1)) of -0.5 or -1 with x2 > x1.
All data were analysed in SPSS version 11 and S-plus ver-
sion 7.0. Length (up to 2 years), height (from 2 years),
weight and target height were expressed as standard devi-
ation score (SDS), using the Dutch reference growth data
for children of Dutch origin, children of Turkish origin,
and children originating from Morocco, respectively [10-
12].
HSDS (Height SDS) is the distance between the individ-
ual's height and the population's mean height for age and
sex, divided by the standard deviation in the population
for the same age and sex: [Individual's height - mean pop-
ulation's height for the same age and sex]/population's SD
for the same age and sex.
A SDS can be easily converted to a percentile, using stand-
ard statistical tables. For growth charts SD lines are more
suitable than percentiles, a.o. because of the the equidis-
tance between the SDS lines. In the Dutch growth charts
(Frediks 2000) -2.5, -2, -1, 0, +1, +2, and +2.5 lines are
drawn, corresponding with P0.6, P2.3, P16, P50, P84, P
97.7, P99.4.
In preterm infants (gestational age < 37 weeks) length and
weight SDS were corrected for gestational age. The intrau-
terine growth curve of the Swedish reference population
[13] was used to express SDS till the age corresponding
with 40 weeks of gestation. Between 40 and 42 weeks an
interpolation between the growth curve of the Swedish
Table 1: Auxological referral criteria taken from the Dutch Consensus Guideline [3]
Description rule Criteria Rule nr.
Absolute height HSDS* < -2.5 (P0.6) 1
Clinical symptoms HSDS* < -1.3 (P10) AND (dysmorphic features OR disproportions) 2
Persistent short stature after born SGA** SGA** AND HSDS* < -1.88 (P3) after the age of 2 years 3
HSDScor 
† : < 10 yr and > 13.4 yr; HSDS* < -1.3 AND HSDS-THSDS < -1.3 4
: < 9 yr and > 12.3 yr
Pubertal age▪: HSDS* < -1.3 AND HSDS-THSDS§ < -1.3 AND pubertal signs 5
: 10 – 13.4 yr;
: 9 – 12.3 yr
Deflection‡ : < 10 yr and > 13.4 yr; T2 – T1 > 1 6a
: < 9 yr and > 12.3 yr (SDS1 – SDS2)/(T2-T1) < -0.25
T2 – T1 > 1 6b
(SDS1 – SDS2) < -1
Pubertal age▪: T2 – T1 > 1 7a
: 10 – 13.4 yr; (SDS1 – SDS2)/(T2-T1) < -0.25
: 9 – 12.3 yr With pubertal signs
T2 – T1 > 1 7b
(SDS1 – SDS2) < -1
With pubertal signs
* HSDS = Height Standard Deviation Score
**SGA = Small for Gestational Age
§ THSDS = Target Height Standard Deviation Score
† HSDScor = HSDS corrected for parental height
‡ Deflection: Deflection is divided into a deflection per time interval (6a and 7a) and an absolute deflection (7b) The deflection per time interval 
represents a downward movement of HSDS (HSDS2-HSDS1) over time (T2-T1), while the absolute deflection is defined by a decrease of HSDS 
over an unspecified time period. In the categories 3–10 and 10–18, T1 > = 3 years, in the other categories T1 > 0.
▪ Pubertal age: If a child does not show any pubertal signs (: genitals > = Tanner stage 2 OR testis volume > = 4 ml; : breast > = Tanner stage 2) 
at this age referral is not necessary.BMC Public Health 2007, 7:77 http://www.biomedcentral.com/1471-2458/7/77
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reference population and that of the Dutch reference pop-
ulation was used. From 42 weeks of gestation till the age
of 2 years, SDS was calculated for age corrected for gesta-
tion, using the Dutch reference growth data.
Parental height was missing in 53% of the children. We
imputed these data under the assumption that the data
were missing at random using Multivariate Imputation by
Chained Equations (MICE) [14]. The method created
multivariate imputations by applying sequential linear
regressions, where each incomplete variable was imputed
conditionally on all variables in an iterative fashion. The
imputation model consisted of the height SDS, weight
SDS, Body-Mass-Index SDS, age, gender, the height of the
other parent, ethnicity, yes or no use of medication influ-
encing growth, and place of attendance of the school doc-
tors. The number of iterations was set to 15. Predictive
mean matching was used to create parental height impu-
tations. The imputation method includes parameter
uncertainty, preserves the multivariate structure in the
data and has good coverage properties [15].
Small for gestational age (SGA) was defined as a birth
weight and/or length SDS < -2, comparing the present
birth weights and lengths with gestational age-matched
reference values from Niklasson et al [13].
The study was approved by the Medical Ethical Commit-
tee of the Leiden University Medical Center and the
Regional Public Health Service Hollands Midden.
Results
From the initial 400 children, 8 were excluded from the
analyses because of incomplete growth data (for example
no date of measurement). The general characteristics of
the remaining 392 children are illustrated in table 2.
Table 3 shows the percentage of referrals in different age
groups, which would have taken place if the Dutch con-
sensus guideline (DCG) had been followed. Almost 80%
of the sample would have been referred at some age
between 0–18 years. Most referrals would take place in the
first 3 years (73.9%); The first height deflection referral
rule (refer if length or height SDS changes more than 0.25
SD per year) would lead to most referrals (69%), followed
by the second height deflection referral rule (refer if height
SDS decreases by more than 1 SD) leading to another
unacceptably high number of referrals (34%). Also the
referral rule based on distance to target height SDS (refer
if the child's height SDS shows a distance of more than 1.3
SD to target height SDS) would lead to a high percentage
of referrals (15%). In the other age groups, especially the
deflection rules would also be responsible for the majority
of referrals.
Table 4 shows the percentage of referrals that had
occurred if the UKCG or the WHO criteria would have
been used. According to the UKCG only one child (0.3%)
would have been referred, while 9–10% would have been
referred according to the WHO. Like the DCG the criteria
of the WHO are mainly met under the age of three years.
Theoretically one could imagine that a deflection away
from the target height SDS in the first 2–3 years of life
could be a suitable referral rule. In this sample, however,
these adapted deflection rules would lead to high percent-
ages of referrals (table 4).
With respect to the actual number of referrals, 34 children
were subject to extra visits to the well-baby clinic because
of growth-retardation. Only one child was actually
referred to a specialised centre for further diagnosis. This
child had a deflection of length before the age of 1 year
and was diagnosed with transient growth retardation due
to dyspepsia.
Discussion
We have confirmed the results of an earlier report in
showing that implementing the Dutch consensus guide-
line for growth monitoring would lead to a high number
of referrals, particularly before the age of 3 years. The
actual number of referrals that was found in practice was
Table 2: General characteristics of the study sample
Total sample
n = 392
Gender Male: n (%) 199 (50.8)




Dysmorphic features: n (%) 16 (4.1)
Disproportion: n (%) 18 (4.6)
Target height SDS: Mean (SD) 0.18 (0.86)
Number of measurements (median) 10BMC Public Health 2007, 7:77 http://www.biomedcentral.com/1471-2458/7/77
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just 1 out of 392 cases, so evidently the proposed guide-
lines were (fortunately) not properly followed. The specif-
icity of the UK Consensus guideline (limited to one cut-
off criterion, i.e. a height < -2.66 SDS at 5 years of age, i.e.
the 0.4th centile) would be better. On the other hand in an
earlier paper we showed that the sensitivity of a height
SDS cut-off to detect Turner syndrome is lower than that
of a cut-off of the distance to target height [7]. The WHO
guideline, as well as two additional criteria with respect to
height deflection away from the target height, would lead
to too many referrals.
To estimate the percentage of pathological conditions pre-
senting with short stature and/or growth failure without
further clinical symptoms or signs, one can refer to several
studies. In the Wessex growth study 180 children (1.25%)
in whom height on screening at school entry was on or
below the 3rd  percentile, were further examined [16].
Among this group 8 children (4.4%) were newly identi-
fied as having an organic disease. Ahmed et al reported in
the Oxford study 7 newly recognized children (3.0%)
with organic disease among the 260 children (1.3% of all
screened children) whose height was below 2 SDS, meas-
ured at the ages of 3 and 4.5 years [17]. From the 555 chil-
dren (0.5% of the screened population) who were
examined for their poor growth (height below the 3rd per-
centile and/or growth rate below 5 cm/yr) in the Utah
growth study 25 children (4.5%) were newly discovered
as having GHD, hypothyroidism or Turner syndrome, and
another 53 children (9.5%) had other medical reasons
[18]. So, one can conclude that out of the (by definition)
2.3% short children (height < -2 SDS) in the population,
3–14% have a condition that warrants additional diag-
nostic tests, corresponding with 0.07 to 0.32% of the pop-
ulation. This low prevalence of pathology in children
presenting with short stature implies that the specificity of
the referral rules should be high, in the order of 98–99%,
in order to keep the number of unnecessary referrals
acceptable.
Table 4: Estimated percentage of referrals according to the UKCG, the WHO guideline, and a parental height deflection rule
Description rule Criteria % referrals % referrals % referrals % referrals
0–3 years 3–10 years 10–18 years 0–18 years
UKCG HSDS§ < -2.67 (P0.4) at age 5 n.a. 0.3 n.a 0.3
Low height for age (HSDS)‡ HSDS§ < - 2 (P2.3) 7.3 3.6 3.2 9.2
Low weight for age (WSDS)‡ WSDS** < -2 (P2.3) 10.0 2.5 3.2 10.5
Parental height deflection rule (0.5 SDS) (HSDS2§ - HSDS1§) < -0.5, AND
| HSDS2§ – TH SDS† | > | HSDS1§ – TH SDS† | 58.8 18.3 28.7 62.0
Parental height deflection rule (1 SDS) (HSDS2§ – HSDS1§) < -1, AND
| HSDS2§ – TH SDS† | > | HSDS1 – TH SDS† | 30.0 3.9 11.6 41.1
* UKCG
§ HSDS = Height Standard Deviation Score
**WSDS = Weight Standard deviation score
†THSDS = Target Height Standard Deviation Score
‡ Rules described by WHO Global database on Child growth and malnutrition.
n.a. = not applicable
Table 3: Estimated percentage of referrals according to the DCG
Description rule Rule nr. % referrals % referrals % referrals % referrals
0–3 years 3–10 year 10–18 year 0–18 years
N = 330 N = 361 N = 345 N = 392
Absolute height 1 1.8 0.8 1.4 3.3
Clinical symptoms 2 2.4 1.1 0.9 2.3
Persistent short stature after born SGA 3 0.0 0.0 0.0 0.0
HSDScor : < 10 yr and > 13.4 yr;
: < 9 yr and > 12.3 yr 4 15.2 5.0 4.9 16.8
: 10 – 13.4 yr;
: 9 – 12.3 yr 5 n.a. n.a. 2.0 (2.0)* 2.0 (2.0)*
Deflection* : < 10 yr and > 13.4 yr;
: < 9 yr and > 12.3 yr 6b 34.2 6.4 15.4 50.5
: 10 – 13.4 yr; 7a n.a. n.a. 3.8 (1.4)* 4.6 (1.3)
: 9 – 12.3 yr 7b n.a. n.a. 22.6 (5.5) 23.0 (4.8)
Total percentage of referrals 73.9 26.0 39.1 79.6
* Data on stage of puberty were frequently missing. Therefore we assumed children with missing data were in puberty at the reference pubertal 
age-period. The number between brackets however represents the exact percentage of referrals in the pubertal age-period, without the 
assumption.
† n.a = not applicableBMC Public Health 2007, 7:77 http://www.biomedcentral.com/1471-2458/7/77
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This study confirmed and expanded the earlier analysis by
Van Buuren et al of the consequences of following the
DCG [4]. In the earlier study the overall referral percent-
age until the age of 10 years was 38% (without deflection
0–3 years) or over 84% (including deflection 0–3 years).
The present study found that almost 80% would have
been referred in the age range 0–18 years.
Short stature has many causes, and the relative prevalence
of these causes varies considerably in the world. This
implies that the objectives of growth monitoring pro-
grams heavily depend on the setting. In developing coun-
tries the principal aim of growth monitoring is to detect
malnutrition. Given this aim the WHO promotes growth
monitoring and research to improve the monitoring pro-
cedures [9,19]. In industrialized countries, however,
where there is less malnutrition, growth monitoring is
aimed at detecting disorders associated with growth retar-
dation without other clinical symptoms or signs, of which
Turner syndrome, Growth Hormone deficiency and
Celiac Disease are most prevalent. We have now shown
that, given the low prevalence of such pathology (0.07 to
0.32% of the population), also the WHO-criteria would
lead to too many referrals.
Most experienced clinicians use three archetypal criteria in
the analysis of growth: the distance of the child's height to
the mean of the population (either expressed as centile or
as SD score), the distance between height SDS and target
height (the gender-corrected mid-parental height) and
growth retardation (i.e. deflection of the growth curve
across the SD-lines or centiles). Our study confirmed that
height SDS deflection over time ("slow deflection")leads
to far too many referrals. In earlier studies we have shown
that height SDS deflection is a poor predictor of congeni-
tal growth hormone deficiency [20] and Turner syndrome
[7]. On the other hand, clinical experience teaches that
crossing the SD-lines (or centiles) can be the first sign of
an acquired GH deficiency (e.g. caused by a brain tumor),
Cushing syndrome or hypothyroidism. The distance to
target height is the best decision rule to detect children
with Turner syndrome, one of the main causes of short
stature [7], but it was left out of the UKCG because of
practical and theoretical problems. For an optimally effi-
cacious and efficient growth monitoring algorithm, a
combination of the three main criteria should be sought.
Conclusion
We have confirmed that the current Dutch consensus
guideline would lead to too many referrals, mainly due to
the deflection of length during the first 3 years of life. The
UKCG leads to far less referrals, but may be insensitive to
detect Turner syndrome, and probably other clinically rel-
evant growth disorders. New guidelines for growth moni-
toring are needed, which combine a low percentage of
false positive results with a good sensitivity. To achieve
these goals more studies are needed on the diagnostic
value and cost-effectiveness of auxological screening for
the diagnosis of various diseases.
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